Compound class:
Synthetic organic
Comment: Compound 10 is a long-acting prodrug of the TGFβR inhibitor BMS-986260 [1]. It contains a matriptase peptide substrate domain, that is cleaved by the protease selectively in the tumour microenvironment. Compound 10 is sufficiently soluble to allow parenteral administration.
We generated the chemical structure shown here from the SMILES provided in the disclosure [1]. This prodrug approach is proposed to limit exposure of non-tumour tissue to the active parent molecule. |
|
References |
1. Zhang Y, Parrish KE, Tortolani DR, Poss MA, Huang A, Wan H, Purandare AV, Donnell AF, Kempson J, Hou X et al.. (2021)
Long-Acting Tumor-Activated Prodrug of a TGFβR Inhibitor. J Med Chem, 64 (21): 15787-15798. [PMID:34704759] |